Navigation Links
Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
Date:8/27/2013

SAN DIEGO, Aug. 27, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Light Study independent Data Monitoring Committee has recently confirmed that sufficient major adverse cardiovascular events (MACE) are expected to occur within the next two months, enabling the interim analysis to be conducted by early December and the potential resubmission of the Contrave® New Drug Application (NDA) by year end. The DMC also recommended that the Light Study continue as planned with no changes to the protocol.

"I'm proud of the progress made by our Light Study team," said Michael Narachi, Chief Executive Officer of Orexigen. "We remain focused on trial execution and launch preparation and look forward to the interim analysis and upcoming regulatory submissions."

Orexigen also today reiterated its plan to submit a Marketing Authorization Application (MAA) for Contrave® to the European Medicines Agency (EMA) in advance of the Light Study interim analysis and to have cardiovascular outcomes data from the Light Study available for the Committee for Medicinal Products for Human Use (CHMP) Day 120 List of Questions.

About Contrave (32 mg naltrexone sustained‐release (SR)/360 mg bupropion SR) for the treatment of obesity: In 2012, Orexigen screened more than 13,000 patients, enrolled more than 10,400 and ultimately completed recruitment of the Light Study with approximately 8,900 randomized patients. The primary objective of the double‐blind, randomized, placebo‐controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave.
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. Fate Therapeutics Strengthens Its iPSC Platform
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 LC Sciences LLC, a ... today that it is seeking beta testers for ... PCR based targeted sequencing technology. The system offers ... enables accurate detection of rare variants. It utilizes ... The company will collaborate with beta testers to ...
(Date:4/16/2015)... and OSAKA, Japan ... Cell Research Application (CiRA) of Kyoto University and ... they will work together to develop clinical applications ... as heart failure, diabetes mellitus, neurological disorders and ... Cell Applications" (T-CiRA) is designed to expedite multiple ...
(Date:4/16/2015)... Capillus, LLC announces plans to expand ... Europe and Asia. The Miami-based medical device manufacturer ... Business Development Director of Svenson Group Europe, as ... professional achievements include increasing the number of Svenson ... the Portuguese marketplace with centers in Lisbon and ...
(Date:4/16/2015)... Grove, IL (PRWEB) April 16, 2015 ... the American Association for Cancer Research (AACR) annual ... the Pennsylvania Convention Center, starting Saturday, April 18, in ... AACR holds claim to title of the oldest and ... journals, provides fellowships and grants, and partners with survivors ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2Regis Technologies Joins American Association for Cancer Research Annual Meeting 2
... , , ... (Nasdaq: MASI ), the inventor of Pulse ... announced that its Radical-7 and Rad-57 Pulse CO-Oximeters have ... Army. AWR certification is a fundamental milestone that allows ...
... Sept. 3 Stryker Corporation (NYSE: SYK ) announced today ... September 15, 2009 - 8:00 a.m. Eastern Time , Morgan ... , September 22, 2009 - 2:00 p.m. Eastern Time , ... , A simultaneous webcast of the Company,s presentations will be ...
... , , TONBRIDGE, ... are trapped in a postcode lottery after Department of Health (DH) ... over who is eligible for the jab. , , ... Health Authority (SHA) has advised all Primary Care Trusts (PCTs) in ...
Cached Biology Technology:Masimo Radical-7(R) and Rad-57(R) Pulse CO-Oximeters(TM) Awarded Airworthiness Release Certification by the United States Army 2Masimo Radical-7(R) and Rad-57(R) Pulse CO-Oximeters(TM) Awarded Airworthiness Release Certification by the United States Army 3Masimo Radical-7(R) and Rad-57(R) Pulse CO-Oximeters(TM) Awarded Airworthiness Release Certification by the United States Army 4Stryker to Present at Investor Conferences 2Health Workers Face Postcode Lottery for Swine Flu Vaccine, Chemist+Druggist Reveals 2
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... WA, famed for its wine, is about to become famous for ... with under global warming. , A fossil coral reef, lying several ... River, points to the high point of the last major sea ... for Coral Reef Studies (CoECRS) consider the reef ?the most southerly ...
... director's cut. In much the same way that numerous films ... footage, a molecular process called alternative splicing enables a single ... created by a team of researchers at Rockefeller University and ... Nature, shows for the first time how the specific location ...
... detail one remembers of an event depends on whether a ... memory. , The research may help to explain why sometimes ... car accident, and yet vividly recall all of the details ... magnetic resonance imaging (fMRI), the scientists were able to view ...
Cached Biology News:Reef warns of sea level rise 2Reef warns of sea level rise 3RNA map provides first comprehensive understanding of alternative splicing 2RNA map provides first comprehensive understanding of alternative splicing 3RNA map provides first comprehensive understanding of alternative splicing 4Memories: It's all in the packaging, scientists say 2
... contains a precipitant to ensure that the samples ... to allow the user to follow the progress ... ABgene ® s proprietary mixture of red ... composition used in ReddyRun™ molecular weight markers. It ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,381-3) ...
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
Gel Loading Buffer contains a precipitant to ensure that the samples sink into the wells and a tracking dye to allow the user to follow the progress of electrophoresis....
Biology Products: